• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Globus Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/15/25 4:41:35 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care
    Get the next $GMED alert in real time by email
    gmed-20250515x8k
    false0001237831DE00012378312025-05-152025-05-15

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 15, 2025  

    GLOBUS MEDICAL, INC.

    (Exact name of registrant as specified in charter)

    DELAWARE

     

    001-35621

     

    04-3744954

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214

    (Address of principal executive offices) (Zip Code)

    (610) 930-1800

    (Registrant’s telephone number, including area code)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbols

    Name of exchange on which registered

    Class A Common Stock, par value $.001 per share

    GMED

    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

    


    ‎


    Item 8.01 Other Events.

    On May 15, 2025, Globus Medical, Inc. issued a news release announcing a program to repurchase $500 million of the Company’s Class A common stock. A copy of the news release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

    Item 9.01. Financial Statements and Exhibits.

    Exhibit No.

    Description

     

     

    99.1

    Press Release dated May 15, 2025

    104

    The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.


    ‎


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    GLOBUS MEDICAL, INC.

     

     

    (Registrant)

     

     

     

    Dated:

    May 15, 2025

    /s/ KEITH PFEIL

     

     

     

     

     

    Keith Pfeil

     

     

    Chief Financial Officer and Chief Operating Officer

    Chief Accounting Officer

    Executive Vice President

     

     

    (Principal Financial Officer)

    Get the next $GMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMED

    DatePrice TargetRatingAnalyst
    5/27/2025Buy → Neutral
    BTIG Research
    1/10/2025$97.00Underperform → Neutral
    BofA Securities
    12/2/2024$83.00 → $100.00Equal-Weight → Overweight
    Morgan Stanley
    8/7/2024$60.00 → $78.00Equal Weight → Overweight
    Wells Fargo
    5/20/2024$60.00 → $80.00Neutral → Overweight
    Piper Sandler
    3/18/2024$60.00Neutral → Buy
    BTIG Research
    10/20/2023$75.00Buy
    ROTH MKM
    9/19/2023$61.00Hold → Buy
    Stifel
    More analyst ratings